RxDoctor Payments Data

Jack Vibbert, DO

Family Medicine · Pell City, ALNPI 1063924868

Payments from drug & device makers

$14,256in general payments, 2019–2025

Across 939 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • GSK$900
  • Amgen$886
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$14,256100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,256 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$62,587
Medicare patients
137
Services billed
1,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide103$124,196
XifaxanRifaximin14$123,068
JardianceEmpagliflozin121$95,625
OzempicSemaglutide75$88,464
EliquisApixaban95$69,111
RybelsusSemaglutide50$47,987
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$45,676
KerendiaFinerenone63$41,290
LinzessLinaclotide44$37,403
Repatha SureclickEvolocumab45$32,871
FarxigaDapagliflozin Propanediol27$24,216
GemtesaVibegron39$21,893
MyrbetriqMirabegron41$19,038
EntrestoSacubitril/Valsartan19$18,376
Synjardy XrEmpagliflozin/Metformin Hcl21$17,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,402$136,451125 claims
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi$277$124,489154 claims
Lilly USA, LLCMounjaro$1,286$124,196103 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$219$123,06814 claims
PfizerEliquis$1,314$69,11195 claims
GSKTrelegy Ellipta$900$45,67654 claims
BayerKerendia$696$41,29063 claims
AbbVieLinzess$1,158$37,40344 claims
AstraZenecaFarxiga$747$24,21627 claims
Sumitomo Pharma America, Inc.Gemtesa$281$21,89339 claims
Astellas Pharma US IncMyrbetriq$187$19,03841 claims
Johnson & JohnsonXarelto$92$8,89816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Pell City

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →